Evidence map›Paper›PMID 38376563›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2024

Changes in wider field swept-source OCT angiography vascular metrics with anti-vascular endothelial growth factor therapy in central retinal vein occlusion.

Peyman Razavi, Grace Baldwin, Itika Garg, Luis Martinez Velazquez, Mauricio Garcia, Jenny Gan, Hanna Choi, Rebecca Zeng, Filippos Vingopoulos, Deeba Husain and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Correlation between macular perfusion status and visual acuity in retinal vein occlusion.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Peyman RazaviHarvard Retinal Imaging Lab, Boston, MA, USA.
Grace BaldwinHarvard Retinal Imaging Lab, Boston, MA, USA.
Itika GargHarvard Retinal Imaging Lab, Boston, MA, USA.
Luis Martinez VelazquezHarvard Retinal Imaging Lab, Boston, MA, USA.
Mauricio GarciaHarvard Retinal Imaging Lab, Boston, MA, USA.
Jenny GanHarvard Retinal Imaging Lab, Boston, MA, USA.
Hanna ChoiHarvard Retinal Imaging Lab, Boston, MA, USA.
Rebecca ZengHarvard Retinal Imaging Lab, Boston, MA, USA.
Filippos VingopoulosHarvard Retinal Imaging Lab, Boston, MA, USA.
Deeba HusainRetina Service, Massachusetts Eye and Ear, Boston, MA, USA.
Leo A KimRetina Service, Massachusetts Eye and Ear, Boston, MA, USA.
Nimesh A PatelRetina Service, Massachusetts Eye and Ear, Boston, MA, USA.
John B MillerHarvard Retinal Imaging Lab, Boston, MA, USA. John_Miller@meei.harvard.edu.ORCID http://orcid.org/0000-0003-0109-9738

Funding

Lions International Fund 530869Lions International Fund Grant 530125
6 · The paper itself

Abstract

purposeTo investigate the impact of anti-VEGF therapy on vascular metrics in eyes with macular edema secondary to central retinal vein occlusion (CRVO) using wider field swept-source OCT angiography (WF SS-OCTA).

methodsWe included 23 eyes with macular edema associated with non-ischemic CRVO from 22 patients treated with anti-VEGF therapy (median number of injections: 5 [2-9]). Changes in vessel density (VD), vessel skeletonized density (VSD), and foveal avascular zone (FAZ) parameters were measured using WF SS-OCTA. Visual acuity (VA) and central subfield thickness (CST) were also measured.

resultsMedian CST decreased significantly from 369 µm (305-531) to 267 µm (243-300, p < 0.001). VD and VSD parameters in 12 × 12 mm images showed significant reductions. For instance, VSD in the whole retina decreased from a median of 13.37 (11.22-13.74) to 11.29 (9.36-12.97, p = 0.013). Additionally, a significant increase in FAZ circularity was found, suggesting improved microvascular integrity. Significant inverse correlations were found between the number of anti-VEGF injections and all VSD and VD parameters on the 12 × 12 mm images (p < 0.05). Notably, the reductions in VSD and VD on 12 × 12 mm angiograms in the deep capillary plexus (DCP) after each injection significantly correlated with increased logMAR VA (worse VA).

conclusionAnti-VEGF therapy in CRVO patients not only mitigates macular edema but also alters the overall microvascular morphology and functionality as revealed by WF SS-OCTA.

Indexed as

Angiogenesis InhibitorsRanibizumabRetinal Vein OcclusionTomography, Optical CoherenceAgedAged, 80 and overBevacizumabFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMacular EdemaMaleMiddle AgedAngiogenesis InhibitorsBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AAnti-VEGFCentral retinal vein occlusion (CRVO)Vascular metricsVessel densityWide field OCTA

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.